Meptid (Meptazinol)

Meptazinol acts as a partial agonist at mu‑opioid receptors in the central nervous system. By partially stimulating these receptors, it reduces the transmission of pain signals while limiting the maximal effect on respiratory function, offering analgesia with a ceiling effect on respiratory depression.

The specific dose and dosing schedule of Meptid are determined by the prescribing clinician based on the patient’s condition, severity of pain, and individual response. Healthcare professionals adjust the regimen according to clinical guidelines and patient needs.

Safety data for meptazinol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Meptid, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Meptid (meptazinol) is a partial mu‑opioid receptor agonist, which provides analgesia with a lower risk of severe respiratory depression compared with full agonists such as morphine. Its ceiling effect on respiratory depression can be advantageous in patients where safety is a priority, though its analgesic potency may be modest relative to stronger opioids.

Meptid should be stored below 25 °C in its original packaging, protected from light and moisture. Avoid freezing the product and keep it out of reach of children. Follow any additional handling instructions provided by the supplier.

Meptid is supplied as an injectable solution for intramuscular or intravenous administration. The route, injection site and rate of infusion are determined by the prescribing clinician and should be performed by qualified healthcare personnel.

The most serious risks include respiratory depression, severe hypotension, seizures, and anaphylactic reactions. Patients should be monitored closely for signs of these events, especially when receiving high doses or when combined with other central nervous system depressants.

Meptid is contraindicated in patients with known hypersensitivity to meptazinol or any component of the formulation, and should be avoided in individuals taking monoamine oxidase inhibitors. Caution is also advised for patients with significant respiratory, hepatic or renal impairment.